A compound of formula (I) wherein n is 0 to 4; m is 0 or 1 with the proviso that the sulphur atom and R.sub.3 are in vicinal position (if m=0 then R.sub.3 is in position 2′, and if m=1 then R.sup.3 is on position 1′); R is ethyl or vinyl; R.sub.1 is hydrogen or (C1-6)alkyl; R.sub.2 is hydrogen or—(C.sub.3-6)cycloalkyl, or—unsubstituted (C.sub.1-6)alkyl, or—(C.sub.1-6)alkyl substituted by one or more of—hydroxy; preferably one or two,—methoxy,—halogen,—(C.sub.3-6)cycloalkyl, or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached form a 5 to 7 membered heterocyclic ring containing at least 1 nitrogen atom or 1 nitrogen and 1 additional heteroatome e. g. selected from N or O, or R.sub.1 is hydroxy and R.sub.2 is formyl; R.sub.3 is OH, OR.sub.4, a halogen atom, or—with the proviso that R.sub.3 is bound to 2′ R.sub.3 represents —O—(CH.sub.2)P—O— with p is 2 or 3; R.sub.4 is unsubstituted (C.sub.1-6)alkyl or (C.sub.3-6)cycloalkyl.

A compound of formula (I) wherein n is 0 to 4; m is 0 or 1 with the proviso that the sulphur atom and R.sub.3 are in vicinal position (if m=0 then R.sub.3 is in position 2′, and if m=1 then R.sup.3 is on position 1′); R is ethyl or vinyl; R.sub.1 is hydrogen or (C1-6)alkyl; R.sub.2 is hydrogen or—(C.sub.3-6)cycloalkyl, or—unsubstituted (C.sub.1-6)alkyl, or—(C.sub.1-6)alkyl substituted by one or more of—hydroxy; preferably one or two,—methoxy,—halogen,—(C.sub.3-6)cycloalkyl, or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached form a 5 to 7 membered heterocyclic ring containing at least 1 nitrogen atom or 1 nitrogen and 1 additional heteroatome e. g. selected from N or O, or R.sub.1 is hydroxy and R.sub.2 is formyl; R.sub.3 is OH, OR.sub.4, a halogen atom, or—with the proviso that R.sub.3 is bound to 2′ R.sub.3 represents —O—(CH.sub.2)P—O— with p is 2 or 3; R.sub.4 is unsubstituted (C.sub.1-6)alkyl or (C.sub.3-6)cycloalkyl.

A salt having a group represented by formula (a): ##STR00001## wherein X.sup.a and X.sup.b each independently represent an oxygen atom or a sulfur atom, X.sup.1 represents a divalent group having an alicyclic hydrocarbon group where a methylene group may be replaced by an oxygen atom or a carbonyl group, and where a hydrogen atom may be replaced by a hydroxy group or a fluorine atom, and * represents a binding site.

A salt having a group represented by formula (a): ##STR00001## wherein X.sup.a and X.sup.b each independently represent an oxygen atom or a sulfur atom, X.sup.1 represents a divalent group having an alicyclic hydrocarbon group where a methylene group may be replaced by an oxygen atom or a carbonyl group, and where a hydrogen atom may be replaced by a hydroxy group or a fluorine atom, and * represents a binding site.

A method of treating Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders comprising: providing a subject with an effective amount of a modified tetracycline or derivative thereof to ameliorate or eliminate the AUD, SUD, tobacco use, pain, or proinflammatory disorder, and wherein the modified tetracycline or derivative thereof has reduced binding to a microbial ribosome and has the formula wherein R1 is acetyl, R2 is OH or acetyl, R3 is acetyl, R4 is H or acetyl, and R5 is acetyl.

##STR00001##

The present invention includes novel molecules and methods for using the same to treat Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders comprising: identifying a subject in need of treatment for at least one of AUD, SUD, pain, or a proinflammatory disorder; and providing the subject with an effective amount of a modified minocycline to ameliorate or eliminate the AUD, SUD, pain, or proinflammatory disorder and that has reduced, or no, antimicrobial activity, wherein the modified tetracycline has a formula, e.g., or the modified doxycycline, minocycline, and tigecycline and their tautomerized structures, where the R-groups shown in the minocycline example above could be different combination of halogen, acetyl ester, methyl ester, and diacetal.

The present invention includes novel molecules and methods for using the same to treat Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders comprising: identifying a subject in need of treatment for at least one of AUD, SUD, pain, or a proinflammatory disorder; and providing the subject with an effective amount of a modified minocycline to ameliorate or eliminate the AUD, SUD, pain, or proinflammatory disorder and that has reduced, or no, antimicrobial activity, wherein the modified tetracycline has a formula, e.g., or the modified doxycycline, minocycline, and tigecycline and their tautomerized structures, where the R-groups shown in the minocycline example above could be different combination of halogen, acetyl ester, methyl ester, and diacetal.

The invention discloses a method for fluoroalkylation of enamines with a fluoro alkyl halide in the presence of a base.

The invention discloses a method for fluoroalkylation of enamines with a fluoro alkyl halide in the presence of a base.

The present disclosure relates to methods of carbon-carbon bond fragmentation.